Edgewise Therapeutics, which received early funding from CureDuchenne, announced positive 6-month interim results from the ongoing ARCH study, an open label study of EDG-5506 in adults with Becker muscular dystrophy.

Edgewise reports that EDG-5506 continues to be well-tolerated, and individuals demonstrate decreased measures of muscle damage and trends toward functional improvements.  The results provide further support that reducing contraction-induced damage in dystrophic muscle has the potential to preserve and improve muscle function while preventing disease progression in dystrophinopathies. These results also help guide their development plan in Duchenne and Becker.

Join CureDuchenne’s live webinar with Edgewise on Wednesday, November 2^nd. REGISTER HERE: https://us02web.zoom.us/webinar/register/WN_HHcm5VUlQVeRZIKMs09E-Q

LETTER TO THE COMMUNITY

PRESS RELEASE: https://investors.edgewisetx.com/news/news-details/2022/Edgewise-Therapeutics-Announces-Positive-6-Month-Interim-Results-from-the-ARCH-Open-Label-Study-of-EDG-5506-in-Adults-with-Becker-Muscular-Dystrophy-BMD/default.aspx